Metastatic Liver Cancer: What to Ask

Most cancers raise one question at this stage: how far has it spread. Hepatocellular carcinoma raises two. How far has it spread, and how much liver is still working.

The second question often decides more than the first. A drug that would help the cancer can be unusable because the liver cannot tolerate it. That is why so much of the conversation sounds like hepatology rather than oncology.

NCI's summary lists functional hepatic reserve among the factors that set treatment. It is measured by the Child-Pugh score. Five things feed that score. Bilirubin. Albumin. Clotting time. Fluid in the abdomen. Confusion.

The reason it matters is simple. Nearly every major first-line trial here enrolled only class A patients. NCI says plainly that there are limited data for people with decompensated liver function. So a class B or class C score does more than describe the liver. It moves someone outside the evidence base.

Bevacizumab blocks a growth signal that blood vessels use. It also raises bleeding risk.

Pressure builds in the portal vein. Blood is pushed into small veins in the esophagus and stomach. Those veins swell into varices, and they can bleed heavily. IMbrave150 set the leading first-line combination. It excluded people whose varices were untreated or only partly treated. NCI lists bleeding risk from active varices among the things weighed when a regimen is chosen.

That is why an endoscopy may be scheduled before the first infusion rather than after it.

For years the standard was sorafenib. The SHARP trial gave median overall survival of 10.7 months with sorafenib against 7.9 months with placebo.

Since 2018 two combinations have beaten it:

• Atezolizumab plus bevacizumab. IMbrave150 enrolled 501 people. None had been treated before. Both drugs were given by infusion every 3 weeks, with the bevacizumab amount based on body weight. The comparison was sorafenib tablets twice a day. Median overall survival was 19.2 months, against 13.4. Response was 30%, against 11%. Grade 3 or higher side effects hit 63% and 57%.
• Durvalumab plus tremelimumab. HIMALAYA enrolled 1,171 people. A single dose of tremelimumab was given alongside durvalumab, which then continued by infusion every 4 weeks. Median overall survival was 16.43 months, against 13.77. Response was 20.1%, against 5.1%.

Two other paths exist. Durvalumab alone was noninferior to sorafenib in that same trial, at 16.56 months. Lenvatinib was noninferior too, at 13.6 months. Its median progression-free survival was 7.4 months, against 3.7.

Checkpoint inhibitors are not for everyone. Autoimmune disease changes the calculation. So does a previous liver transplant. Both are worth raising before a regimen is picked, not after.

The multikinase inhibitors carry a different problem. NCI notes that treatment-related adverse events can make adherence to sorafenib difficult, particularly in a population that already has liver disease.

NCI lists transarterial embolization and chemoembolization as options in nonmetastatic disease. Once cancer has spread beyond the liver, they are no longer on that list.

The summary names three situations where blocking the artery is relatively contraindicated. Portal hypertension. Portal vein thrombosis. Clinical jaundice. In a liver already tipping, these procedures can push it further.

Portal vein involvement matters for staging too. In the AJCC system, a tumor of any size involving a major branch of the portal or hepatic vein is T4.

Transplant has a narrow door. NCI cites the Milan criteria: a single tumor under 5 cm, or two to three tumors each under 3 cm. For people who meet them, 5-year overall survival is roughly 70%.

Radiation has been tested here as well. In NRG/RTOG 1112, adding stereotactic body radiation to sorafenib gave median overall survival of 15.8 months against 12.3 months. That difference was not statistically significant.

After sorafenib, NCI lists regorafenib, cabozantinib and ramucirumab, plus pembrolizumab and nivolumab with ipilimumab.

Ramucirumab has a threshold attached. It is used only when alpha-fetoprotein is 400 ng/mL or higher. REACH-2 required that level. Median overall survival there was 8.5 months, against 7.3 with placebo. The earlier REACH trial did not require it, and the benefit was not statistically significant.

NCI is candid about the remaining gap: the most effective second-line treatment after first-line atezolizumab and bevacizumab has not been determined.

Most hepatocellular carcinoma sits on top of chronic liver disease. So it is fair to ask whether hepatitis B or hepatitis C is being treated at the same time. The liver that has to survive cancer treatment is the same liver the virus is damaging.

Alpha-fetoprotein deserves the same caution. NCI says AFP is not sensitive or specific enough to diagnose liver cancer on its own. It can be raised by intrahepatic cholangiocarcinoma. It can be raised by liver metastases from colon cancer. A mass plus a high AFP does not settle the diagnosis. But if the level was high to begin with, it can be used to watch for recurrence.

For the wider framework, cancer staging explains what stage does and does not decide, and palliative care covers symptom support given alongside treatment rather than after it.

• What is my Child-Pugh class right now, and which options does it close?
• Has an endoscopy looked for varices before any bevacizumab-based plan?
• Has the cancer grown into the portal vein?
• Between atezolizumab-bevacizumab and durvalumab-tremelimumab, what tips the choice for me?
• Does my autoimmune history, or a past transplant, rule out immunotherapy?
• Is hepatitis B or hepatitis C being treated at the same time?
• What was my alpha-fetoprotein at diagnosis?
• If this first treatment stops working, what is the plan after it?

• Call 911 or go to an emergency department if you vomit blood or pass black tarry stools. That is bleeding from varices, and MedlinePlus says to go straight to an emergency room. Go too if you become confused, very drowsy, or cannot be woken properly. Liver failure can flip into that state quickly.
• Call your care team the same day if you have a temperature of 100.4°F (38°C) or higher or shaking chills, especially with a swollen or painful belly, which can mean the fluid in the abdomen is infected. Call the same day if the yellow in your eyes or skin is deepening, if your belly is swelling quickly, or if your sleep has flipped so you are awake at night and drowsy by day. That last one is often the first sign of the confusion above. On atezolizumab or durvalumab, call the same day for diarrhea several times more often than usual, or a new cough or breathlessness.
• Systemic chemotherapy makes that fever urgent rather than same-day. CDC describes a fever during chemotherapy as a medical emergency. Phone the oncology line as soon as you see 100.4°F (38°C), day or night, and go to an emergency department if nobody answers.
• Call your care team within a day or two if you are bruising more easily, or getting nosebleeds or bleeding gums. Do the same for new leg swelling, for sore or blistered palms and soles on sorafenib, lenvatinib or regorafenib, and for home blood pressure readings running high on bevacizumab.

• NCI PDQ — Adult Primary Liver Cancer Treatment (Health Professional Version)
• NCI PDQ — Adult Primary Liver Cancer Treatment (Patient Version)
• MedlinePlus — Bleeding esophageal varices
• MedlinePlus — Hepatic encephalopathy
• NCI — Immune Checkpoint Inhibitors